

Mentz Rj

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3938371/publications.pdf>

Version: 2024-02-01

373
papers

13,427
citations

34076

52
h-index

33869

99
g-index

396
all docs

396
docs citations

396
times ranked

13451
citing authors

#	ARTICLE	IF	CITATIONS
1	Hypertensive Diseases in Pregnancy and Kidney Function Later in Life. Mayo Clinic Proceedings, 2022, 97, 78-87.	1.4	2
2	Physical Rehabilitation in Older Patients Hospitalized with Acute Heart Failure and Diabetes: Insights from REHAB-HF. American Journal of Medicine, 2022, 135, 82-90.	0.6	8
3	Polypharmacy in Palliative Care for Advanced Heart Failure: The PAL-HF Experience. Journal of Cardiac Failure, 2022, 28, 334-338.	0.7	2
4	Economic Outcomes of Rehabilitation Therapy in Older Patients With Acute Heart Failure in the REHAB-HF Trial. JAMA Cardiology, 2022, 7, 140.	3.0	5
5	Dysglycemia and incident heart failure among blacks: The jackson heart study. American Heart Journal, 2022, 245, 1-9.	1.2	3
6	Race Differences in Quality of Life following a Palliative Care Intervention in Patients with Advanced Heart Failure: Insights from the Palliative Care in Heart Failure Trial. Journal of Palliative Medicine, 2022, 25, 296-300.	0.6	3
7	Exploring the pragmatic-explanatory spectrum across cardiovascular clinical trials. Contemporary Clinical Trials, 2022, 113, 106646.	0.8	3
8	An evaluation of torsemide in patients with heart failure and renal disease. Expert Review of Cardiovascular Therapy, 2022, 20, 5-11.	0.6	6
9	Clinical trajectory of patients with a worsening heart failure event and reduced ventricular ejection fraction. American Heart Journal, 2022, 245, 110-116.	1.2	3
10	Quantifying Benefit-Risk Preferences for Heart Failure Devices: A Stated-Preference Study. Circulation: Heart Failure, 2022, 15, CIRCHEARTFAILURE121008797.	1.6	7
11	Emergency Department Visits Versus Hospital Readmissions Among Patients Hospitalized for Heart Failure. Journal of Cardiac Failure, 2022, 28, 916-923.	0.7	5
12	Prevalence and Prognostic Significance of Polyvascular Disease in Patients Hospitalized With Acute Decompensated Heart Failure: The ARIC Study. Journal of Cardiac Failure, 2022, 28, 1267-1277.	0.7	3
13	Transthyretin V142I Genetic Variant and Cardiac Remodeling, Injury, and Heart Failure Risk in Black Adults. JACC: Heart Failure, 2022, 10, 129-138.	1.9	9
14	Optimal Background Pharmacological Therapy for Heart Failure Patients in Clinical Trials. Journal of the American College of Cardiology, 2022, 79, 504-510.	1.2	21
15	Heart Month – A Historical Look and Simple “Walk” of Acknowledgement in the Present. Journal of Cardiac Failure, 2022, 28, 169-170.	0.7	1
16	The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial. Nature Medicine, 2022, 28, 568-574.	15.2	341
17	Depressive Symptoms and Incident Heart Failure in the Jackson Heart Study: Differential Risk Among Black Men and Women. Journal of the American Heart Association, 2022, 11, e022514.	1.6	9
18	Medical Therapy During Hospitalization for Heart Failure With Reduced Ejection Fraction: The VICTORIA Registry. Journal of Cardiac Failure, 2022, 28, 1063-1077.	0.7	23

#	ARTICLE	IF	CITATIONS
19	In-Hospital Outcomes in Pregnancy After Heart Transplantation. American Journal of Cardiology, 2022, 172, 68-72.	0.7	2
20	Inclusion and diversity in clinical trials: Actionable steps to drive lasting change. Contemporary Clinical Trials, 2022, 116, 106740.	0.8	39
21	Finerenone in patients with chronic kidney disease and type 2 diabetes with and without heart failure: a prespecified subgroup analysis of the <sc>FIDELIOÖD&K</sc> trial. European Journal of Heart Failure, 2022, 24, 996-1005.	2.9	23
22	Spirituality in Patients With HeartÁFailure. JACC: Heart Failure, 2022, 10, 217-226.	1.9	12
23	Effects of Empagliflozin on Symptoms, Physical Limitations, and Quality of Life in Patients Hospitalized for Acute Heart Failure: Results From the EMPULSE Trial. Circulation, 2022, 146, 279-288.	1.6	65
24	Medication Trajectory and Treatment Patterns in Medicare Patients With Heart Failure and Reduced Ejection Fraction. Journal of Cardiac Failure, 2022, 28, 1349-1354.	0.7	6
25	Donation After Circulatory Death in Heart Transplantation: History, Outcomes, Clinical Challenges, and Opportunities to Expand the Donor Pool. Journal of Cardiac Failure, 2022, 28, 1456-1463.	0.7	18
26	Prioritizing Quad Therapy and the Path Forward in Guideline-Directed Medical Therapy for Patients With Heart Failure With Reduced Ejection Fraction. Circulation, 2022, 145, 1105-1107.	1.6	0
27	Sleep Breathing Disorders in Heart Failure. Cardiology Clinics, 2022, 40, 183-189.	0.9	2
28	Trends in HF Hospitalizations AmongÁYoung Adults in the United States From 2004 to 2018. JACC: Heart Failure, 2022, 10, 350-362.	1.9	21
29	International Collaborations in Heart Failure: JCF in Latin America. Journal of Cardiac Failure, 2022, 28, 695-696.	0.7	0
30	The need for increased pragmatism in cardiovascular clinical trials. Nature Reviews Cardiology, 2022, 19, 737-750.	6.1	22
31	Metabolomic Profiling of the Effects of Dapagliflozin in Heart Failure With Reduced Ejection Fraction: DEFINE-HF. Circulation, 2022, 146, 808-818.	1.6	33
32	Intervention Adherence in REHABÁHF: Predictors and Relationship With Physical Function, Quality of Life, and Clinical Events. Journal of the American Heart Association, 2022, 11, .	1.6	5
33	Effect of race on cardiometabolic responses to once-weekly exenatide: insights from the Exenatide Study of Cardiovascular Event Lowering (EXSCEL). Cardiovascular Diabetology, 2022, 21, .	2.7	3
34	Frailty Status Modifies the Efficacy of Exercise Training Among Patients With Chronic Heart Failure and Reduced Ejection Fraction: An Analysis From the HF-ACTION Trial. Circulation, 2022, 146, 80-90.	1.6	32
35	Body surface area and medication dosing in patients with heart failure with reduced ejection fraction. Trends in Cardiovascular Medicine, 2021, 31, 111-116.	2.3	4
36	Cognition, Physical Function, and Quality of Life in Older Patients With Acute Decompensated Heart Failure. Journal of Cardiac Failure, 2021, 27, 286-294.	0.7	21

#	ARTICLE	IF	CITATIONS
37	Comparison of Dyspnea Measurement Instruments in Acute Heart Failure: The DYSPNEA-AHF Pilot Study. <i>Journal of Cardiac Failure</i> , 2021, 27, 607-609.	0.7	1
38	Differences between patients with cardiovascular disease and cancer referred for palliative care. <i>American Heart Journal</i> , 2021, 233, 5-9.	1.2	2
39	Implications of peripheral oedema in heart failure with preserved ejection fraction: a heart failure network analysis. <i>ESC Heart Failure</i> , 2021, 8, 662-669.	1.4	5
40	Plasma Volume Status and Its Association With In-Hospital and Postdischarge Outcomes in Decompensated Heart Failure. <i>Journal of Cardiac Failure</i> , 2021, 27, 297-308.	0.7	4
41	The Future of the <i>Journal of Cardiac Failure</i> : A Reinvigorated Focus on People, Partnerships and Presentation. <i>Journal of Cardiac Failure</i> , 2021, 27, 1.	0.7	3
42	Sodium-Glucose Cotransporter 2 Inhibitors in Patients With Heart Failure With Reduced Ejection Fraction. <i>Circulation</i> , 2021, 143, 322-325.	1.6	4
43	Racial Differences and Temporal Obesity Trends in Heart Failure with Preserved Ejection Fraction. <i>Journal of the American Geriatrics Society</i> , 2021, 69, 1309-1318.	1.3	4
44	Patterns of Change in Individual Domains of the Kansas City Cardiomyopathy Questionnaire With a Palliative Care Intervention for Patients With Advanced Heart Failure: Insights from PAL-HF. <i>Journal of Cardiac Failure</i> , 2021, 27, 1476-1478.	0.7	1
45	Acute cardiovascular hospitalizations and illness severity before and during the COVID-19 pandemic. <i>Clinical Cardiology</i> , 2021, 44, 656-664.	0.7	6
46	Beta-blocker and ACE-inhibitor dosing as a function of body surface area: From the HF-ACTION trial. <i>American Heart Journal</i> , 2021, 233, 1-4.	1.2	1
47	Egg Consumption and Risk of Cardiovascular Disease: a Critical Review. <i>Current Emergency and Hospital Medicine Reports</i> , 2021, 9, 25-37.	0.6	3
48	Diversity, Equity and Inclusion at the <i>Journal of Cardiac Failure</i> . <i>Journal of Cardiac Failure</i> , 2021, 27, 263-264.	0.7	3
49	Cigarette Smoking, Incident Coronary Heart Disease, and Coronary Artery Calcification in Black Adults: The Jackson Heart Study. <i>Journal of the American Heart Association</i> , 2021, 10, e017320.	1.6	19
50	Predicting major adverse limb events in individuals with type 2 diabetes: Insights from the EXSCEL trial. <i>Diabetic Medicine</i> , 2021, 38, e14552.	1.2	5
51	Thoughtful selection and use of scientific terms in clinical research: the case of "pragmatic" trials. <i>Journal of Investigative Medicine</i> , 2021, 69, 1056-1058.	0.7	6
52	Relationship of physical function with quality of life in older patients with acute heart failure. <i>Journal of the American Geriatrics Society</i> , 2021, 69, 1836-1845.	1.3	5
53	Prognostic Role of Prior Heart Failure Hospitalization Among Patients Hospitalized for Worsening Chronic Heart Failure. <i>Circulation: Heart Failure</i> , 2021, 14, e007871.	1.6	24
54	Update on the Impact of Comorbidities on the Efficacy and Safety of Heart Failure Medications. <i>Current Heart Failure Reports</i> , 2021, 18, 132-143.	1.3	1

#	ARTICLE	IF	CITATIONS
55	The Universal Definition of Heart Failure: Perspectives from Diverse Stakeholders. <i>Journal of Cardiac Failure</i> , 2021, 27, 386.	0.7	1
56	Splanchnic Nerve Block Mediated Changes in Stressed Blood Volume in Heart Failure. <i>JACC: Heart Failure</i> , 2021, 9, 293-300.	1.9	28
57	Quality outcomes, healthcare resource utilization and costs in Medicare patients with chronic heart failure with reduced ejection fraction with and without a worsening event. <i>Journal of Medical Economics</i> , 2021, 24, 698-705.	1.0	6
58	Meta-Analysis of Efficacy of Sacubitril/Valsartan in Heart Failure With Preserved Ejection Fraction. <i>American Journal of Cardiology</i> , 2021, 145, 165-168.	0.7	8
59	Pragmatic Design of Randomized Clinical Trials for Heart Failure. <i>JACC: Heart Failure</i> , 2021, 9, 325-335.	1.9	22
60	Estimated Glomerular Filtration Rate Variability in Patients With Heart Failure and Chronic Kidney Disease. <i>Journal of Cardiac Failure</i> , 2021, 27, 1175-1184.	0.7	3
61	Worsening Heart Failure Events in HFpEF. <i>JACC: Heart Failure</i> , 2021, 9, 383-385.	1.9	1
62	Randomized Placebo-Controlled Trial of Ferric Carboxymaltose in Heart Failure With Iron Deficiency: Rationale and Design. <i>Circulation: Heart Failure</i> , 2021, 14, e008100.	1.6	30
63	Sex Differences in Clinical Course and Patient-Reported Outcomes Among Patients Hospitalized for Heart Failure. <i>JACC: Heart Failure</i> , 2021, 9, 336-345.	1.9	23
64	Drugs of Abuse and Heart Failure. <i>Journal of Cardiac Failure</i> , 2021, 27, 1260-1275.	0.7	13
65	Older Patients With Acute Decompensated Heart Failure Who Live Alone: An Analysis From the REHAB-HF Trial. <i>Journal of Cardiac Failure</i> , 2021, , .	0.7	2
66	The Cost-Effectiveness of Palliative Care: Insights from the PAL-HF Trial. <i>Journal of Cardiac Failure</i> , 2021, 27, 662-669.	0.7	8
67	Survival in Patients with Non-Ischemic Cardiomyopathy with Preserved versus Reduced Ejection Fraction. <i>CJC Open</i> , 2021, 3, 1333-1340.	0.7	2
68	Development and Validation of Machine Learning-Based Race-Specific Models to Predict 10-Year Risk of Heart Failure: A Multicohort Analysis. <i>Circulation</i> , 2021, 143, 2370-2383.	1.6	56
69	Representativeness of the VICTORIA Trial Population in Clinical Practice: Analysis of the PINNACLE Registry. <i>Journal of Cardiac Failure</i> , 2021, 27, 1374-1381.	0.7	13
70	A Case for Re-Gifting. <i>JACC: Case Reports</i> , 2021, 3, 1010-1012.	0.3	0
71	Physical Rehabilitation for Older Patients Hospitalized for Heart Failure. <i>New England Journal of Medicine</i> , 2021, 385, 203-216.	13.9	267
72	Physical Activity, Subclinical Myocardial Injury, and Risk of Heart Failure Subtypes in Black Adults. <i>JACC: Heart Failure</i> , 2021, 9, 484-493.	1.9	10

#	ARTICLE	IF	CITATIONS
73	Regional Adiposity and Risk of Heart Failure and Mortality: The Jackson Heart Study. <i>Journal of the American Heart Association</i> , 2021, 10, e020920.	1.6	14
74	The Additive Prognostic Value of Serial Plasma Interleukin-6 Levels over Changes in Brain Natriuretic Peptide in Patients with Acute Heart Failure. <i>Journal of Cardiac Failure</i> , 2021, 27, 808-811.	0.7	7
75	Temporal Trends and Factors Associated With Cardiac Rehabilitation Participation Among Medicare Beneficiaries With Heart Failure. <i>JACC: Heart Failure</i> , 2021, 9, 471-481.	1.9	38
76	Sacubitril/Valsartan Initiation and Postdischarge Adherence Among Patients Hospitalized for Heart Failure. <i>Journal of Cardiac Failure</i> , 2021, 27, 826-836.	0.7	30
77	Patient Phenotypes and SGLT-2 Inhibition in Type 2 Diabetes. <i>JACC: Heart Failure</i> , 2021, 9, 568-577.	1.9	8
78	Clinical and Echocardiographic Characteristics of Patients Hospitalized With Acute Versus Chronic Heart Failure With Preserved Ejection Fraction (From the ARIC Study). <i>American Journal of Cardiology</i> , 2021, 158, 59-65.	0.7	1
79	Participation in a Heart Failure Clinical Trial. <i>Circulation: Heart Failure</i> , 2021, 14, e008242.	1.6	12
80	Clinical Effectiveness of Sacubitril/Valsartan Among Patients Hospitalized for Heart Failure With Reduced Ejection Fraction. <i>Journal of the American Heart Association</i> , 2021, 10, e021459.	1.6	10
81	Sleep quality, depressive symptoms, and transplant outcomes: Follow-up analyses from the ADAPT prospective pilot study. <i>General Hospital Psychiatry</i> , 2021, 72, 53-58.	1.2	3
82	Sex-Differences in Cause of Death for Patients Hospitalized for Heart Failure With Reduced Versus Preserved Ejection Fraction (from the ASCEND-HF Trial). <i>American Journal of Cardiology</i> , 2021, 154, 123-126.	0.7	1
83	Early Identification of Patients at Risk for Incident Heart Failure With Preserved Ejection Fraction: Novel Approach to Echocardiographic Trends. <i>Journal of Cardiac Failure</i> , 2021, 27, 942-948.	0.7	0
84	Sacubitril/Valsartan Adherence and Postdischarge Outcomes Among Patients Hospitalized for Heart Failure With Reduced Ejection Fraction. <i>JACC: Heart Failure</i> , 2021, 9, 876-886.	1.9	19
85	Clinical Outcome Predictions for the VeriCiguaT Global Study in Subjects With Heart Failure With Reduced Ejection Fraction (VICTORIA) Trial. <i>Journal of Cardiac Failure</i> , 2021, 27, 949-956.	0.7	8
86	Physical Functioning in Heart Failure With Preserved Ejection Fraction. <i>Journal of Cardiac Failure</i> , 2021, 27, 1002-1016.	0.7	2
87	Characteristics and Outcomes of Patients With Heart Failure With Reduced Ejection Fraction After a Recent Worsening Heart Failure Event. <i>Journal of the American Heart Association</i> , 2021, 10, e021276.	1.6	6
88	Early diuretic strategies and the association with In-hospital and Post-discharge outcomes in acute heart failure. <i>American Heart Journal</i> , 2021, 239, 110-119.	1.2	3
89	Rehabilitation Intervention in Older Patients With Acute Heart Failure With Preserved Versus Reduced Ejection Fraction. <i>JACC: Heart Failure</i> , 2021, 9, 747-757.	1.9	32
90	OptiVol for Volume Assessment in Patients With Continuous Flow Left Ventricular Assist Device. <i>ASAIO Journal</i> , 2021, 67, 192-195.	0.9	2

#	ARTICLE	IF	CITATIONS
91	Temporal Trends and Prognosis of Physical Examination Findings in Patients With Acute Decompensated Heart Failure: The ARIC Study Community Surveillance. <i>Circulation: Heart Failure</i> , 2021, , CIRCHEARTFAILURE121008403.	1.6	1
92	Polyvascular disease and increased risk of cardiovascular events in patients with type 2 diabetes: Insights from the EXSCEL trial. <i>Atherosclerosis</i> , 2021, 338, 1-6.	0.4	6
93	In-Hospital Initiation of Sodium-Glucose Cotransporter-2 Inhibitors for Heart Failure With Reduced Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2021, 78, 2004-2012.	1.2	48
94	Following Our Hearts: Prioritizing Self-care and Wellness. <i>Journal of Cardiac Failure</i> , 2021, 27, 1163-1164.	0.7	1
95	Relationship of Nonalcoholic Fatty Liver Disease and Heart Failure With Preserved Ejection Fraction. <i>JACC Basic To Translational Science</i> , 2021, 6, 918-932.	1.9	41
96	JCF Year-In-Review 2021 and the Path Forward. <i>Journal of Cardiac Failure</i> , 2021, 27, 1307-1309.	0.7	2
97	Influence of donor brain death duration on outcomes following heart transplantation: A United Network for Organ Sharing Registry analysis. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2020, 159, 1345-1353.e2.	0.4	18
98	Increasing the United States heart transplant donor pool with donation after circulatory death. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2020, 159, e307-e309.	0.4	53
99	Sleep Breathing Disorders in Heart Failure. <i>Heart Failure Clinics</i> , 2020, 16, 45-51.	1.0	32
100	Association of obesity with cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease: Insights from TECOS. <i>American Heart Journal</i> , 2020, 219, 47-57.	1.2	45
101	Within-Trial Evaluation of Medical Resources, Costs, and Quality of Life Among Patients With Type 2 Diabetes Participating in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL). <i>Diabetes Care</i> , 2020, 43, 374-381.	4.3	4
102	Renal Outcomes in Patients Bridged to Heart Transplant With a Left Ventricular Assist Device. <i>Annals of Thoracic Surgery</i> , 2020, 110, 567-574.	0.7	5
103	Association between body surface area and prescribed doses of guideline-directed medications among international patients with heart failure and reduced ejection fraction. <i>European Journal of Heart Failure</i> , 2020, 22, 754-758.	2.9	4
104	Confirming the Bidirectional Nature of the Association Between Severe Hypoglycemic and Cardiovascular Events in Type 2 Diabetes: Insights From EXSCEL. <i>Diabetes Care</i> , 2020, 43, 643-652.	4.3	38
105	Impact of baseline covariate imbalance on bias in treatment effect estimation in cluster randomized trials: Race as an example. <i>Contemporary Clinical Trials</i> , 2020, 88, 105775.	0.8	5
106	Microvascular and Cardiovascular Outcomes According to Renal Function in Patients Treated With Once-Weekly Exenatide: Insights From the EXSCEL Trial. <i>Diabetes Care</i> , 2020, 43, 446-452.	4.3	63
107	Tobacco smoking in patients with heart failure and coronary artery disease: A 20-year experience at Duke University Medical Center. <i>American Heart Journal</i> , 2020, 230, 25-34.	1.2	6
108	PROVIDE-HF primary results: Patient-Reported Outcomes in Investigation following Initiation of Drug therapy with Entresto (sacubitril/valsartan) in heart failure. <i>American Heart Journal</i> , 2020, 230, 35-43.	1.2	8

#	ARTICLE	IF	CITATIONS
109	Improving the Design of Future PCI Trials for Stable Coronary Artery Disease. <i>Journal of the American College of Cardiology</i> , 2020, 76, 435-450.	1.2	7
110	Biomarkers in Advanced Heart Failure. <i>Circulation: Heart Failure</i> , 2020, 13, e006840.	1.6	3
111	Cigarette Smoking and Incident Stroke in Blacks of the Jackson Heart Study. <i>Journal of the American Heart Association</i> , 2020, 9, e014990.	1.6	19
112	Clinical applications of machine learning in the diagnosis, classification, and prediction of heart failure. <i>American Heart Journal</i> , 2020, 229, 1-17.	1.2	85
113	In-hospital outcomes after bariatric surgery in patients with heart failure. <i>American Heart Journal</i> , 2020, 230, 59-62.	1.2	5
114	Relation of Low Normal Left Ventricular Ejection Fraction to Heart Failure Hospitalization in Blacks (From the Jackson Heart Study). <i>American Journal of Cardiology</i> , 2020, 136, 100-106.	0.7	3
115	Sample size requirements for detecting treatment effect heterogeneity in cluster randomized trials. <i>Statistics in Medicine</i> , 2020, 39, 4218-4237.	0.8	18
116	Effect of once-weekly exenatide on estimated glomerular filtration rate slope depends on baseline renal risk: A post hoc analysis of the EXSCEL trial. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 2493-2498.	2.2	26
117	Effects of Liraglutide on Worsening Renal Function Among Patients With Heart Failure With Reduced Ejection Fraction. <i>Circulation: Heart Failure</i> , 2020, 13, e006758.	1.6	8
118	Cost-effectiveness of Contemporary Statin Use Guidelines With or Without Coronary Artery Calcium Assessment in African American Individuals. <i>JAMA Cardiology</i> , 2020, 5, 871.	3.0	24
119	Elevated Uric Acid Prevalence and Clinical Outcomes in Patients with Heart Failure with Preserved Ejection Fraction: Insights from RELAX. <i>American Journal of Medicine</i> , 2020, 133, e716-e721.	0.6	12
120	Hypertensive diseases in pregnancy, cardiac structure and function later in life: Insights from the Genetic Epidemiology Network of Arteriopathy (GENOA) study. <i>Pregnancy Hypertension</i> , 2020, 21, 184-190.	0.6	4
121	Temporal Trends in Prevalence and Prognostic Implications of Comorbidities Among Patients With Acute Decompensated Heart Failure. <i>Circulation</i> , 2020, 142, 230-243.	1.6	59
122	Outcomes and cost among Medicare beneficiaries hospitalized for heart failure assigned to accountable care organizations. <i>American Heart Journal</i> , 2020, 226, 13-23.	1.2	7
123	Exploring the Possible Impact of Unbalanced Open-Label Drop-In of Glucose-Lowering Medications on EXSCEL Outcomes. <i>Circulation</i> , 2020, 141, 1360-1370.	1.6	9
124	The burden of non-cardiac comorbidities and association with clinical outcomes in an acute heart failure trial—insights from ASCEND-HF. <i>European Journal of Heart Failure</i> , 2020, 22, 1022-1031.	2.9	27
125	Regional adiposity and heart failure with preserved ejection fraction. <i>European Journal of Heart Failure</i> , 2020, 22, 1540-1550.	2.9	69
126	Pre-discharge initiation of Ivabradine in the Management of Heart Failure: Results of the PRIME-HF Trial. <i>American Heart Journal</i> , 2020, 223, 98-105.	1.2	12

#	ARTICLE	IF	CITATIONS
127	Association between potassium level and outcomes in heart failure with reduced ejection fraction: a cohort study from the Swedish Heart Failure Registry. <i>European Journal of Heart Failure</i> , 2020, 22, 1390-1398.	2.9	33
128	Pharmacological management of atrial fibrillation in patients with heart failure with reduced ejection fraction: review of current knowledge and future directions. <i>Expert Review of Cardiovascular Therapy</i> , 2020, 18, 85-101.	0.6	2
129	A Novel In-hospital Congestion Score to Risk Stratify Patients Admitted for Worsening Heart Failure (from ASCEND-HF). <i>Journal of Cardiovascular Translational Research</i> , 2020, 13, 540-548.	1.1	5
130	Spironolactone metabolite concentrations in decompensated heart failure: insights from the ATHENA-HF trial. <i>European Journal of Heart Failure</i> , 2020, 22, 1451-1461.	2.9	12
131	Sex Differences in Quality of Life and Clinical Outcomes in Patients With Advanced Heart Failure. <i>Circulation: Heart Failure</i> , 2020, 13, e006134.	1.6	29
132	A care pathway for the cardiovascular complications of COVID-19: Insights from an institutional response. <i>American Heart Journal</i> , 2020, 225, 3-9.	1.2	12
133	Cardiovascular implications of idiopathic pulmonary fibrosis: A way forward together?. <i>American Heart Journal</i> , 2020, 226, 69-74.	1.2	7
134	Comparison of Characteristics and Outcomes of Patients With Heart Failure With Preserved Ejection Fraction With Versus Without Hyperuricemia or Gout. <i>American Journal of Cardiology</i> , 2020, 127, 64-72.	0.7	8
135	Reassessing Recipient Mortality Under the New Heart Allocation System. <i>JACC: Heart Failure</i> , 2020, 8, 548-556.	1.9	83
136	Ultrafiltration in Acute Heart Failure: Implications of Ejection Fraction and Early Response to Treatment From CARRESS-HF. <i>Journal of the American Heart Association</i> , 2020, 9, e015752.	1.6	11
137	Timing of cardiac resynchronization therapy device implantation in heart failure patients and its association with outcomes. <i>Clinical Cardiology</i> , 2019, 42, 256-263.	0.7	9
138	Population-Attributable Risk for Cardiovascular Disease Associated With Hypertension in Black Adults. <i>JAMA Cardiology</i> , 2019, 4, 1194.	3.0	48
139	Representativeness of a Heart Failure Trial by Race and Sex. <i>JACC: Heart Failure</i> , 2019, 7, 980-992.	1.9	30
140	Increased eGFR Variability is Observed in Patients with HFrEF Compared to no HF or HFpEF in the Setting of Chronic Kidney Disease. <i>Journal of Cardiac Failure</i> , 2019, 25, S92.	0.7	0
141	Trends in Place of Death for Individuals With Cardiovascular Disease in the United States. <i>Journal of the American College of Cardiology</i> , 2019, 74, 1943-1946.	1.2	17
142	Depressive symptoms, physical activity, and clinical events: The ADAPT prospective pilot study. <i>Clinical Transplantation</i> , 2019, 33, e13710.	0.8	14
143	Incorporation of Biomarkers Into Risk Assessment for Allocation of Antihypertensive Medication According to the 2017 ACC/AHA High Blood Pressure Guideline. <i>Circulation</i> , 2019, 140, 2076-2088.	1.6	49
144	Patterns of Change in Quality of Life with a Palliative Care Intervention for Patients with Advanced Heart Failure: Insights from PAL-HF. <i>Journal of Cardiac Failure</i> , 2019, 25, S154-S155.	0.7	1

#	ARTICLE	IF	CITATIONS
145	Effects of exenatide and open-label SGLT2 inhibitor treatment, given in parallel or sequentially, on mortality and cardiovascular and renal outcomes in type 2 diabetes: insights from the EXSCel trial. <i>Cardiovascular Diabetology</i> , 2019, 18, 138.	2.7	48
146	Haemoconcentration during treatment of acute heart failure with cardiorenal syndrome: from the CARRESS-HF trial. <i>European Journal of Heart Failure</i> , 2019, 21, 1472-1476.	2.9	2
147	Subcutaneous Furosemide in the Treatment of Patients with Decompensated Heart Failure: Data from the Sub-Q Pilot Studies. <i>Journal of Cardiac Failure</i> , 2019, 25, S75.	0.7	3
148	International variation in characteristics and clinical outcomes of patients with type 2 diabetes and heart failure: Insights from TECOS. <i>American Heart Journal</i> , 2019, 218, 57-65.	1.2	4
149	Effect of Once-Weekly Exenatide in Patients With Type 2 Diabetes Mellitus With and Without Heart Failure and Heart Failure-Related Outcomes. <i>Circulation</i> , 2019, 140, 1613-1622.	1.6	58
150	Type 2 Diabetes Mellitus and Heart Failure: A Scientific Statement From the American Heart Association and the Heart Failure Society of America: This statement does not represent an update of the 2017 ACC/AHA/HFSA heart failure guideline update. <i>Circulation</i> , 2019, 140, e294-e324.	1.6	342
151	African Americans With Advanced Heart Failure Are More Likely to Die in a Health Care Facility Than at Home or in Hospice: An Analysis From the PAL-HF Trial. <i>Journal of Cardiac Failure</i> , 2019, 25, 693-694.	0.7	9
152	Medical Management of Heart Failure With Reduced Ejection Fraction in Patients With Advanced Renal Disease. <i>JACC: Heart Failure</i> , 2019, 7, 371-382.	1.9	36
153	Characteristics and Trends Among Patients With Cardiovascular Disease Referred to Palliative Care. <i>JAMA Network Open</i> , 2019, 2, e192375.	2.8	43
154	10-Year Risk Equations for Incident Heart Failure in the General Population. <i>Journal of the American College of Cardiology</i> , 2019, 73, 2388-2397.	1.2	107
155	PATIENTS WITH DIABETES AND PERIPHERAL ARTERIAL DISEASE: RESULTS FROM THE EXSCel TRIAL. <i>Journal of the American College of Cardiology</i> , 2019, 73, 2040.	1.2	1
156	Clinical profiles in acute heart failure: an urgent need for a new approach. <i>ESC Heart Failure</i> , 2019, 6, 464-474.	1.4	42
157	Associations of Dietary Cholesterol or Egg Consumption With Incident Cardiovascular Disease and Mortality. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 1081.	3.8	238
158	Neck circumference and cardiovascular outcomes: Insights from the Jackson Heart Study. <i>American Heart Journal</i> , 2019, 212, 72-79.	1.2	15
159	The continuous heart failure spectrum: moving beyond an ejection fraction classification. <i>European Heart Journal</i> , 2019, 40, 2155-2163.	1.0	195
160	Top Ten Tips Palliative Care Clinicians Should Know About Caring for Patients with Left Ventricular Assist Devices. <i>Journal of Palliative Medicine</i> , 2019, 22, 437-441.	0.6	11
161	Spirolactone in Acute Heart Failure Patients With Renal Dysfunction and Risk Factors for Diuretic Resistance: From the ATHENA-HF Trial. <i>Canadian Journal of Cardiology</i> , 2019, 35, 1097-1105.	0.8	19
162	Targeting Natriuretic Peptide Levels in Heart Failure with Therapy: Does It Really Mark the Spot?. <i>Current Heart Failure Reports</i> , 2019, 16, 250-256.	1.3	1

#	ARTICLE	IF	CITATIONS
163	Patients Accept Mortality Risk for Improvements in Physical Functioning in Secondary Mitral Regurgitation. <i>Journal of Cardiac Failure</i> , 2019, 25, S149.	0.7	1
164	Identifying responders to oral iron supplementation in heart failure with a reduced ejection fraction: a post-hoc analysis of the IRONOUT-HF trial. <i>Journal of Cardiovascular Medicine</i> , 2019, 20, 223-225.	0.6	15
165	Impact of Age on Comorbidities and Outcomes in Heart Failure With Reduced Ejection Fraction. <i>JACC: Heart Failure</i> , 2019, 7, 1056-1065.	1.9	21
166	Patients' Willingness to Accept Mitral Valve Procedure-Associated Risks Varies Across Severity of Heart Failure Symptoms. <i>Circulation: Cardiovascular Interventions</i> , 2019, 12, e008051.	1.4	14
167	Frailty Among Older Decompensated Heart Failure Patients. <i>JACC: Heart Failure</i> , 2019, 7, 1079-1088.	1.9	61
168	Clinical Effectiveness of Sacubitril/valsartan among Patients Hospitalized for Heart Failure with Reduced Ejection Fraction. <i>Journal of Cardiac Failure</i> , 2019, 25, 937.	0.7	3
169	Clinical Outcomes in Patients With Type 2 Diabetes Mellitus and Peripheral Artery Disease. <i>Circulation: Cardiovascular Interventions</i> , 2019, 12, e008018.	1.4	25
170	Relationship between changing patient-reported outcomes and subsequent clinical events in patients with chronic heart failure: insights from HF-ACTION. <i>European Journal of Heart Failure</i> , 2019, 21, 63-70.	2.9	42
171	Potassium Abnormalities Across the Spectrum of Heart Failure. <i>JACC: Heart Failure</i> , 2019, 7, 77-79.	1.9	2
172	Association of Cardiac Injury and Malignant Left Ventricular Hypertrophy With Risk of Heart Failure in African Americans. <i>JAMA Cardiology</i> , 2019, 4, 51.	3.0	38
173	Hospice Care for Heart Failure: Challenges Faced by Hospice Staff in a Predominantly Rural Setting. <i>Journal of Palliative Medicine</i> , 2019, 22, 7-8.	0.6	8
174	Reduction of Cardiovascular Risk and Improved Estimated Glomerular Filtration Rate by SGLT2 Inhibitors, Including Dapagliflozin, Is Consistent Across the Class: An Analysis of the Placebo Arm of EXSCEL. <i>Diabetes Care</i> , 2019, 42, 318-326.	4.3	23
175	Phrenic Nerve Stimulation for the Treatment of Central Sleep Apnea: A Pooled Cohort Analysis. <i>Journal of Clinical Sleep Medicine</i> , 2019, 15, 1747-1755.	1.4	20
176	Prevalent digoxin use and subsequent risk of death or hospitalization in ambulatory heart failure patients with a reduced ejection fraction—Findings from the Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training (HF-ACTION) randomized controlled trial. <i>American Heart Journal</i> , 2018, 199, 97-104.	1.2	9
177	The role of angiotensin receptor neprilysin inhibitors in cardiovascular disease—existing evidence, knowledge gaps, and future directions. <i>European Journal of Heart Failure</i> , 2018, 20, 963-972.	2.9	35
178	Interaction of Body Mass Index on the Association Between N-Terminal Pro-B-Type Natriuretic Peptide and Morbidity and Mortality in Patients With Acute Heart Failure: Findings From ASCEND-HF (Acute Study) Tj ETQq0 0.0 rgBT /Overlock 10 Association, 2018, 7, .	1.6	12
179	Cigarette Smoking and Incident Heart Failure. <i>Circulation</i> , 2018, 137, 2572-2582.	1.6	96
180	Early versus late readmission during the vulnerable phase following hospitalization for heart failure: reply. <i>European Journal of Heart Failure</i> , 2018, 20, 1166-1166.	2.9	2

#	ARTICLE	IF	CITATIONS
181	Traveling the Interstices of Data Sharing. <i>JACC: Heart Failure</i> , 2018, 6, 533-535.	1.9	1
182	Outpatient Worsening Heart Failure as a Target for Therapy. <i>JAMA Cardiology</i> , 2018, 3, 252.	3.0	90
183	Early impact of guideline publication on angiotensin-receptor neprilysin inhibitor use among patients hospitalized for heart failure. <i>American Heart Journal</i> , 2018, 200, 134-140.	1.2	8
184	Sudden cardiac death after acute heart failure hospital admission: insights from ASCEND-HF. <i>European Journal of Heart Failure</i> , 2018, 20, 525-532.	2.9	29
185	Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis. <i>Lancet Diabetes and Endocrinology</i> , 2018, 6, 105-113.	5.5	451
186	Trends and outcomes of cardiac transplantation from donors dying of drug intoxication. <i>American Heart Journal</i> , 2018, 199, 92-96.	1.2	10
187	Is Time of the Essence? The Impact of Time of Hospital Presentation in Acute Heart Failure. <i>JACC: Heart Failure</i> , 2018, 6, 298-307.	1.9	4
188	Paving a Better Path for Patients Dying of Heart Disease. <i>Circulation</i> , 2018, 137, 1216-1217.	1.6	5
189	Intentional and unintentional medication non-adherence in African Americans: Insights from the Jackson Heart Study. <i>American Heart Journal</i> , 2018, 200, 51-59.	1.2	15
190	Indications for and outcomes of therapeutic plasma exchange after cardiac transplantation: A single center retrospective study. <i>Journal of Clinical Apheresis</i> , 2018, 33, 469-479.	0.7	2
191	Strategies for supporting intervention fidelity in the rehabilitation therapy in older acute heart failure patients (REHAB-HF) trial. <i>Contemporary Clinical Trials</i> , 2018, 64, 118-127.	0.8	24
192	Aetiology, timing and clinical predictors of early vs. late readmission following index hospitalization for acute heart failure: insights from ASCEND-HF. <i>European Journal of Heart Failure</i> , 2018, 20, 304-314.	2.9	42
193	Influence of Baseline Physical Activity Level on Exercise Training Response and Clinical Outcomes in Heart Failure. <i>JACC: Heart Failure</i> , 2018, 6, 1011-1019.	1.9	22
194	Association Between Regional Adipose Tissue Distribution and Risk of Heart Failure Among Blacks. <i>Circulation: Heart Failure</i> , 2018, 11, e005629.	1.6	24
195	Effects of Once-Weekly Exenatide on Clinical Outcomes in Patients With Preexisting Cardiovascular Disease. <i>Circulation</i> , 2018, 138, 2576-2578.	1.6	13
196	Physical Function, Frailty, Cognition, Depression, and Quality of Life in Hospitalized Adults ≥60 Years With Acute Decompensated Heart Failure With Preserved Versus Reduced Ejection Fraction. <i>Circulation: Heart Failure</i> , 2018, 11, e005254.	1.6	129
197	Association of Renin-Angiotensin Inhibitor Treatment With Mortality and Heart Failure Readmission in Patients With Transcatheter Aortic Valve Replacement. <i>JAMA - Journal of the American Medical Association</i> , 2018, 320, 2231.	3.8	72
198	Effect of Once-Weekly Exenatide on Clinical Outcomes According to Baseline Risk in Patients With Type 2 Diabetes Mellitus: Insights From the EXSCel Trial. <i>Journal of the American Heart Association</i> , 2018, 7, e009304.	1.6	19

#	ARTICLE	IF	CITATIONS
199	Relationship Between Enrolling Country Income Level and Patient Profile, Protocol Completion, and Trial End Points. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2018, 11, e004783.	0.9	13
200	Causes of Death Among Patients with and without Diabetes and Chronic Heart Failure: Insights from the HF-ACTION and ASIAN-HF Registry. <i>Journal of Cardiac Failure</i> , 2018, 24, S69.	0.7	0
201	Top Ten Tips for Palliative Care Clinicians Caring for Heart Failure Patients. <i>Journal of Palliative Medicine</i> , 2018, 21, 1646-1650.	0.6	6
202	Reassessing the Role of Surrogate End Points in Drug Development for Heart Failure. <i>Circulation</i> , 2018, 138, 1039-1053.	1.6	24
203	Rate pressure product and the components of heart rate and systolic blood pressure in hospitalized heart failure patients with preserved ejection fraction: Insights from ASCEND-HF. <i>Clinical Cardiology</i> , 2018, 41, 945-952.	0.7	22
204	Hyperkalemia in Heart Failure: Probably Not OâœKâœ. <i>Journal of the American Heart Association</i> , 2018, 7, .	1.6	10
205	Multiâœethnic comparisons of diabetes in heart failure with reduced ejection fraction: insights from the HFâœACTION trial and the ASIANâœHF registry. <i>European Journal of Heart Failure</i> , 2018, 20, 1281-1289.	2.9	23
206	Adding Troponin to the Puzzle of Heart Failure With Preserved Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2018, 72, 41-44.	1.2	1
207	Renal Function and Exercise Training in Ambulatory Heart Failure Patients With a Reduced Ejection Fraction. <i>American Journal of Cardiology</i> , 2018, 122, 999-1007.	0.7	5
208	Worsening renal function during decongestion among patients hospitalized for heart failure: Findings from the Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness (ESCAPE) trial. <i>American Heart Journal</i> , 2018, 204, 163-173.	1.2	42
209	Loop diuretic adjustments in patients with chronic heart failure: Insights from HF-ACTION. <i>American Heart Journal</i> , 2018, 205, 133-141.	1.2	13
210	Sudden Death After Hospitalization for Heart Failure With Reduced Ejection Fraction (from the Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 30	0.7	6
211	Palliative care and hospital readmissions in patients with advanced heart failure: Insights from the PAL-HF trial. <i>American Heart Journal</i> , 2018, 204, 202-204.	1.2	14
212	Vaccination Trends in Patients With HeartâœFailure. <i>JACC: Heart Failure</i> , 2018, 6, 844-855.	1.9	30
213	Relation of Volume Overload to Clinical Outcomes in Acute Heart Failure (From ASCEND-HF). <i>American Journal of Cardiology</i> , 2018, 122, 1506-1512.	0.7	16
214	The emerging role of novel antihyperglycemic agents in the treatment of heart failure and diabetes: A focus on cardiorenal outcomes. <i>Clinical Cardiology</i> , 2018, 41, 1259-1267.	0.7	10
215	Relation of Early Repolarization (J Point Elevation) to Mortality in Blacks (from the Jackson Heart) Tj ETQq1 1 0.784314 rgBT /Overlock 9	0.7	9
216	Home-Time After Discharge Among Patients Hospitalized With Heart Failure. <i>Journal of the American College of Cardiology</i> , 2018, 71, 2643-2652.	1.2	72

#	ARTICLE	IF	CITATIONS
217	Renal Outcomes in the EXenatide Study of Cardiovascular Event Lowering (EXSCEL). Diabetes, 2018, 67, .	0.3	42
218	EXSCELâ€™ Once-Weekly Exenatide Reduces Medical Resource Utilization in Patients with Type 2 Diabetes Mellitus. Diabetes, 2018, 67, 1319-P.	0.3	0
219	Impact of SGLT2 Inhibitors (SGLT2i) on Cardiovascular (CV) Risk and Estimated Glomerular Filtration Rate (eGFR) in the EXSCEL Placebo Group. Diabetes, 2018, 67, 130-LB.	0.3	0
220	Can Vaccinations Improve Heart Failure Outcomes?. JACC: Heart Failure, 2017, 5, 194-203.	1.9	47
221	Return on Investment in Implantable Devices. JACC: Heart Failure, 2017, 5, 213-215.	1.9	1
222	Tailoring mineralocorticoid receptor antagonist therapy in heart failure patients: are we moving towards a personalized approach?. European Journal of Heart Failure, 2017, 19, 974-986.	2.9	29
223	Achieving a Maximally Tolerated Î²-Blocker Dose in Heart Failure Patients. Journal of the American College of Cardiology, 2017, 69, 2542-2550.	1.2	41
224	Trajectory of Congestion Metrics by Ejection Fraction in Patients With Acute Heart Failure (from the Tj ETQq0 0 0 rgBT /Overlock 10 Tf	0.7	15
225	Pulmonary Hypertension Is Associated With a Higher Risk of Heart Failure Hospitalization and Mortality in Patients With Chronic Kidney Disease. Circulation: Heart Failure, 2017, 10, .	1.6	35
226	Biomarker Profiles of Acute Heart Failure Patients With a Mid-Range Ejection Fraction. JACC: Heart Failure, 2017, 5, 507-517.	1.9	78
227	Hospitalization for Recently Diagnosed Versus Worsening Chronic Heart Failure. Journal of the American College of Cardiology, 2017, 69, 3029-3039.	1.2	69
228	Aerobic exercise training and general health status in ambulatory heart failure patients with a reduced ejection fractionâ€™ Findings from the Heart Failure and A Controlled Trial Investigating Outcomes of Exercise Training (HF-ACTION) trial. American Heart Journal, 2017, 186, 130-138.	1.2	27
229	TIMING AND CLINICAL PREDICTORS OF EARLY VERSUS LATE READMISSION AMONG PATIENTS HOSPITALIZED FOR ACUTE HEART FAILURE: INSIGHTS FROM ASCEND-HF. Journal of the American College of Cardiology, 2017, 69, 766.	1.2	2
230	HEMOCONCENTRATION DURING MANAGEMENT OF PATIENTS WITH ACUTE HEART FAILURE AND CARDIORENAL SYNDROME: INSIGHTS FROM CARRESS-HF. Journal of the American College of Cardiology, 2017, 69, 767.	1.2	0
231	EFFECTS OF AGE AND COMORBIDITIES ON OUTCOMES IN PATIENTS WITH HEART FAILURE FROM HF-ACTION. Journal of the American College of Cardiology, 2017, 69, 908.	1.2	1
232	Global Variations in Patient Populations and Outcomes in Heart Failure Clinical Trials. Current Heart Failure Reports, 2017, 14, 30-39.	1.3	6
233	Exercise Training in Patients With Chronic Heart Failure and Atrial Fibrillation. Journal of the American College of Cardiology, 2017, 69, 1683-1691.	1.2	45
234	Early Adoption of Sacubitril/Valsartan for Patients With Heart Failure With Reduced Ejection Fraction. JACC: Heart Failure, 2017, 5, 305-309.	1.9	101

#	ARTICLE	IF	CITATIONS
235	Site Principal Investigators in Multicenter Clinical Trials. <i>Circulation</i> , 2017, 135, 1185-1187.	1.6	10
236	Baseline characteristics of patients enrolled in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL). <i>American Heart Journal</i> , 2017, 187, 1-9.	1.2	49
237	Subclinical Atherosclerosis, Statin Eligibility, and Outcomes in African American Individuals. <i>JAMA Cardiology</i> , 2017, 2, 644.	3.0	30
238	Rehabilitation Therapy in Older Acute Heart Failure Patients (REHAB-HF) trial: Design and rationale. <i>American Heart Journal</i> , 2017, 185, 130-139.	1.2	71
239	Body Weight Change During and After Hospitalization for Acute Heart Failure: Patient Characteristics, Markers of Congestion, and Outcomes. <i>JACC: Heart Failure</i> , 2017, 5, 1-13.	1.9	84
240	Socioeconomic and partner status in chronic heart failure: Relationship to exercise capacity, quality of life, and clinical outcomes. <i>American Heart Journal</i> , 2017, 183, 54-61.	1.2	33
241	Loop Diuretic Change in Patients with Chronic Heart Failure: Insights From HF-ACTION. <i>Journal of Cardiac Failure</i> , 2017, 23, S65-S66.	0.7	0
242	The Burden of Non-Cardiac Comorbidities in Acute Heart Failure: Insights From ASCEND-HF. <i>Journal of Cardiac Failure</i> , 2017, 23, S109.	0.7	0
243	Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2017, 377, 1228-1239.	13.9	1,455
244	Building the case for aerobic exercise in ambulatory patients with heart failure and a reduced ejection fraction. <i>American Heart Journal</i> , 2017, 192, e3.	1.2	1
245	Palliative Care in Heart Failure. <i>Journal of the American College of Cardiology</i> , 2017, 70, 331-341.	1.2	425
246	Efficacy and Safety of Spironolactone in Acute Heart Failure. <i>JAMA Cardiology</i> , 2017, 2, 950.	3.0	199
247	Multinational and multiethnic variations in health-related quality of life in patients with chronic heart failure. <i>American Heart Journal</i> , 2017, 191, 75-81.	1.2	31
248	Management of newly treated diabetes in Medicare beneficiaries with and without heart failure. <i>Clinical Cardiology</i> , 2017, 40, 38-45.	0.7	13
249	Amiodarone use in patients listed for heart transplant is associated with increased 1-year post-transplant mortality. <i>Journal of Heart and Lung Transplantation</i> , 2017, 36, 202-210.	0.3	49
250	Resting Heart Rate and Long-term Outcomes Among the African American Population. <i>JAMA Cardiology</i> , 2017, 2, 172.	3.0	23
251	Insufficient reduction in heart rate during hospitalization despite beta-blocker treatment in acute decompensated heart failure: insights from the ASCEND-HF trial. <i>European Journal of Heart Failure</i> , 2017, 19, 241-249.	2.9	22
252	Efficacy and Safety of Tolvaptan in Patients Hospitalized With Acute Heart Failure. <i>Journal of the American College of Cardiology</i> , 2017, 69, 1399-1406.	1.2	171

#	ARTICLE	IF	CITATIONS
253	Can 2 Pills a Day Keep Readmission Away?. Journal of the American College of Cardiology, 2016, 68, 249-251.	1.2	3
254	Statins and Exercise Training Response in Heart Failure Patients. JACC: Heart Failure, 2016, 4, 617-624.	1.9	9
255	The clinical course of health status and association with outcomes in patients hospitalized for heart failure: insights from ASCEND-HF. European Journal of Heart Failure, 2016, 18, 306-313.	2.9	36
256	Nesiritide in patients hospitalized for acute heart failure: does timing matter? Implication for future acute heart failure trials. European Journal of Heart Failure, 2016, 18, 684-692.	2.9	14
257	The Targeting Acute Congestion with Tolvaptan in Congestive Heart Failure Study: A Randomized, Double blind, Placebo-Controlled Trial in Acute Heart Failure. Journal of Cardiac Failure, 2016, 22, 939.	0.7	0
258	Associations Between Blood Pressure and Outcomes Among Blacks in the Jackson Heart Study. Journal of the American Heart Association, 2016, 5, .	1.6	5
259	Assessment of Administrative Data to Identify Acute Myocardial Infarction in Electronic Health Records. Journal of the American College of Cardiology, 2016, 67, 2441-2442.	1.2	8
260	Exercise Training in Patients with Chronic Heart Failure and Atrial Fibrillation: Results from the HF-ACTION Trial. Journal of Cardiac Failure, 2016, 22, S71.	0.7	2
261	Regional Differences during Acute Heart Failure Hospitalizations of Patients with Heart Failure with Preserved Ejection Fraction: Insights From ASCEND-HF. Journal of Cardiac Failure, 2016, 22, S27.	0.7	0
262	Ranolazine for Treatment of Angina or Dyspnea in Hypertrophic Cardiomyopathy Patients (RHYME). Journal of the American College of Cardiology, 2016, 68, 1815-1817.	1.2	30
263	Influence of Clinical Trial Site Enrollment on Patient Characteristics, Protocol Completion, and End Points. Circulation: Heart Failure, 2016, 9, .	1.6	15
264	Usefulness of Palliative Care to Complement the Management of Patients on Left Ventricular Assist Devices. American Journal of Cardiology, 2016, 118, 733-738.	0.7	23
265	Acute heart failure in the young: Clinical characteristics and biomarker profiles. International Journal of Cardiology, 2016, 221, 1067-1072.	0.8	11
266	Changes in Dyspnea Status During Hospitalization and Postdischarge Health-Related Quality of Life in Patients Hospitalized for Heart Failure: Findings From the EVEREST Trial. Circulation: Heart Failure, 2016, 9, .	1.6	20
267	Development and validation of a risk model for in-hospital worsening heart failure from the Acute Decompensated Heart Failure National Registry (ADHERE). American Heart Journal, 2016, 178, 198-205.	1.2	14
268	Implications of Using Different Definitions on Outcomes in Worsening Heart Failure. Circulation: Heart Failure, 2016, 9, .	1.6	7
269	Relation of Angina Pectoris to Outcomes, Quality of Life, and Response to Exercise Training in Patients With Chronic Heart Failure (from HF-ACTION). American Journal of Cardiology, 2016, 118, 1211-1216.	0.7	11
270	A Gordian knot: disentangling comorbidities in heart failure. European Journal of Heart Failure, 2016, 18, 759-761.	2.9	1

#	ARTICLE	IF	CITATIONS
271	Cardiorenal Interactions. Heart Failure Clinics, 2016, 12, 335-347.	1.0	11
272	Heart Failure Clinical Trials in East and Southeast Asia. JACC: Heart Failure, 2016, 4, 419-427.	1.9	48
273	Geographic Differences in Patients in a Global Acute Heart Failure Clinical Trial (from the ASCEND-HF) Tj ETQq1 1 0.784314 rgBT /Over 26	0.7	26
274	The Obesity and Heart Failure Epidemics Among African Americans: Insights From the Jackson Heart Study. Journal of Cardiac Failure, 2016, 22, 589-597.	0.7	19
275	Relation of Elevated Heart Rate in Patients With Heart Failure With Reduced Ejection Fraction to One-Year Outcomes and Costs. American Journal of Cardiology, 2016, 117, 946-951.	0.7	23
276	Rationale and design of the EXenatide Study of Cardiovascular Event Lowering (EXSCEL) trial. American Heart Journal, 2016, 174, 103-110.	1.2	82
277	Serum Osmolality and Postdischarge Outcomes After Hospitalization for Heart Failure. American Journal of Cardiology, 2016, 117, 1144-1150.	0.7	23
278	Torsemide Versus Furosemide in Patients With Acute Heart Failure (from the ASCEND-HF Trial). American Journal of Cardiology, 2016, 117, 404-411.	0.7	47
279	Response to Exercise Training and Outcomes in Patients With Heart Failure and Diabetes Mellitus: Insights From the HF-ACTION Trial. Journal of Cardiac Failure, 2016, 22, 485-491.	0.7	40
280	Clinical Implications of Serum Albumin Levels in Acute Heart Failure: Insights From DOSE-AHF and ROSE-AHF. Journal of Cardiac Failure, 2016, 22, 884-890.	0.7	35
281	Comorbidities in Heart Failure: Are There Gender Differences?. Current Heart Failure Reports, 2016, 13, 1-12.	1.3	37
282	Good Clinical Practice Guidance and Pragmatic Clinical Trials. Circulation, 2016, 133, 872-880.	1.6	79
283	Targeting Comorbidities in Elderly Patients With Heart Failure: The OPTIMIZE-HFPEF Trial. Journal of Cardiac Failure, 2016, 22, 545-547.	0.7	1
284	Discharge heart rate and β -blocker dose in patients hospitalized with heart failure: Findings from the OPTIMIZE-HF registry. American Heart Journal, 2016, 173, 172-178.	1.2	28
285	Hemodynamic Predictors of Heart Failure Morbidity and Mortality: Fluid or Flow?. Journal of Cardiac Failure, 2016, 22, 182-189.	0.7	118
286	Evaluation of Novel Metrics of Symptom Relief in Acute Heart Failure: The Worst Symptom Score. Journal of Cardiac Failure, 2016, 22, 853-858.	0.7	7
287	Air Pollution in Patients With Heart Failure. JACC: Heart Failure, 2016, 4, 65-67.	1.9	9
288	Cardiac transplantation for older patients: Characteristics and outcomes in the septuagenarian population. Journal of Heart and Lung Transplantation, 2016, 35, 362-369.	0.3	36

#	ARTICLE	IF	CITATIONS
289	Clinical predictors and outcomes of patients with left ventricular thrombus following ST-segment elevation myocardial infarction. <i>Journal of Thrombosis and Thrombolysis</i> , 2016, 41, 365-373.	1.0	21
290	Pathophysiology and clinical evaluation of acute heart failure. <i>Nature Reviews Cardiology</i> , 2016, 13, 28-35.	6.1	120
291	Volume Assessment and Management: Medical and Device Therapies. , 2016, , 125-163.		0
292	Prognostic Significance of Depression in Blacks With Heart Failure. <i>Circulation: Heart Failure</i> , 2015, 8, 497-503.	1.6	14
293	Differences in health care use and outcomes by the timing of in-hospital worsening heart failure. <i>American Heart Journal</i> , 2015, 170, 1124-1132.	1.2	8
294	Elevated Heart Rate in Patients with Heart Failure with Reduced Ejection Fraction: Associations with One-Year Survival and Costs. <i>Journal of Cardiac Failure</i> , 2015, 21, S121-S122.	0.7	2
295	Is there a role for albumin and C-reactive protein levels for prognostication in acute heart failure?. <i>Journal of Cardiovascular Medicine</i> , 2015, 16, 401-403.	0.6	1
296	Early vs. late worsening heart failure during acute heart failure hospitalization: insights from the PROTECT trial. <i>European Journal of Heart Failure</i> , 2015, 17, 697-706.	2.9	24
297	Torsemide Versus Furosemide in Heart Failure Patients. <i>Journal of Cardiovascular Pharmacology</i> , 2015, 65, 438-443.	0.8	28
298	Worsening heart failure during hospitalization for acute heart failure: Insights from the Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure (ASCEND-HF). <i>American Heart Journal</i> , 2015, 170, 298-305.	1.2	38
299	A Call for Collaboration. <i>Journal of the American College of Cardiology</i> , 2015, 65, 2348-2351.	1.2	7
300	Relief and Recurrence of Congestion During and After Hospitalization for Acute Heart Failure. <i>Circulation: Heart Failure</i> , 2015, 8, 741-748.	1.6	235
301	Identifying Barriers and Practical Solutions to Conducting Site-Based Research in North America. <i>Heart Failure Clinics</i> , 2015, 11, 581-589.	1.0	5
302	Psychosocial Factors, Exercise Adherence, and Outcomes in Heart Failure Patients. <i>Circulation: Heart Failure</i> , 2015, 8, 1044-1051.	1.6	52
303	Ventricular Conduction and Long-Term Heart Failure Outcomes and Mortality in African Americans. <i>Circulation: Heart Failure</i> , 2015, 8, 243-251.	1.6	20
304	Comparative effectiveness of torsemide versus furosemide in heart failure patients: insights from the PROTECT trial. <i>Future Cardiology</i> , 2015, 11, 585-595.	0.5	23
305	COPD in Heart Failure. <i>Chest</i> , 2015, 147, 586-588.	0.4	4
306	Decongestion Strategies and Renin-Angiotensin-Aldosterone System Activation in Acute Heart Failure. <i>JACC: Heart Failure</i> , 2015, 3, 97-107.	1.9	95

#	ARTICLE	IF	CITATIONS
307	Impact of Diabetes on Epidemiology, Treatment, and Outcomes of Patients With Heart Failure. <i>JACC: Heart Failure</i> , 2015, 3, 136-145.	1.9	265
308	A reappraisal of loop diuretic choice in heart failure patients. <i>American Heart Journal</i> , 2015, 169, 323-333.	1.2	83
309	Using Natriuretic Peptides for Selection of Patients in Acute Heart Failure Clinical Trials. <i>American Journal of Cardiology</i> , 2015, 116, 1304-1310.	0.7	5
310	Enrollment in Heart Failure Clinical Trials: Insights Into Which Entry Criteria Exclude Patients. <i>Journal of Cardiac Failure</i> , 2015, 21, 608-609.	0.7	4
311	End-of-life Heart Failure Care in the United States. <i>Heart Failure Clinics</i> , 2015, 11, 615-623.	1.0	11
312	Angiotensin Receptor Neprilysin Inhibition in Heart Failure: Mechanistic Action and Clinical Impact. <i>Journal of Cardiac Failure</i> , 2015, 21, 741-750.	0.7	28
313	Longitudinal Strain in Heart Failure With Preserved Ejection Fraction. <i>Circulation</i> , 2015, 132, 368-370.	1.6	13
314	Combination decongestion therapy in hospitalized heart failure: loop diuretics, mineralocorticoid receptor antagonists and vasopressin antagonists. <i>Expert Review of Cardiovascular Therapy</i> , 2015, 13, 799-809.	0.6	10
315	Improving cardiovascular clinical trials conduct in the United States: Recommendation from clinicians, researchers, sponsors, and regulators. <i>American Heart Journal</i> , 2015, 169, 305-314.	1.2	20
316	Patient Selection in Heart Failure With Preserved Ejection Fraction Clinical Trials. <i>Journal of the American College of Cardiology</i> , 2015, 65, 1668-1682.	1.2	116
317	Atherosclerosis: Recent trials, new targets and future directions. <i>International Journal of Cardiology</i> , 2015, 192, 72-81.	0.8	28
318	Tolvaptan in Patients Hospitalized With Acute Heart Failure. <i>Circulation: Heart Failure</i> , 2015, 8, 997-1005.	1.6	26
319	Hospitalized Heart Failure in the United States. <i>Heart Failure Clinics</i> , 2015, 11, 591-601.	1.0	3
320	Cardiac Contractility Modulation: The Next Cardiac Resynchronization Therapy or Another Renal Sympathetic Denervation?. <i>Journal of Cardiac Failure</i> , 2015, 21, 24-26.	0.7	2
321	Relation of Dyspnea Severity on Admission for Acute Heart Failure With Outcomes and Costs. <i>American Journal of Cardiology</i> , 2015, 115, 75-81.	0.7	35
322	Abstract 17304: Sudden Cardiac Death After Acute Heart Failure Hospitalization: Insights From ASCEND-HF. <i>Circulation</i> , 2015, 132, .	1.6	0
323	In-Hospital Worsening Heart Failure and Associations With Mortality, Readmission, and Healthcare Utilization. <i>Journal of the American Heart Association</i> , 2014, 3, .	1.6	48
324	Persistent angina pectoris in ischaemic cardiomyopathy: increased rehospitalization and major adverse cardiac events. <i>European Journal of Heart Failure</i> , 2014, 16, 854-860.	2.9	16

#	ARTICLE	IF	CITATIONS
325	Noncardiac Comorbidities in Heart Failure With Reduced Versus Preserved Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2014, 64, 2281-2293.	1.2	424
326	Decongestion in acute heart failure. <i>European Journal of Heart Failure</i> , 2014, 16, 471-482.	2.9	113
327	Heart Failure With Preserved Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2014, 63, 251-258.	1.2	33
328	Global Perspectives in Hospitalized Heart Failure: Regional and Ethnic Variation in Patient Characteristics, Management, and Outcomes. <i>Current Heart Failure Reports</i> , 2014, 11, 416-427.	1.3	46
329	Relation of Serum Uric Acid Levels and Outcomes Among Patients Hospitalized for Worsening Heart Failure With Reduced Ejection Fraction (from the Efficacy of Vasopressin Antagonism in Heart Failure) Trial. <i>Journal of the American College of Cardiology</i> , 2014, 63, 1414-1421.	1.0	7
330	The Palliative Care in Heart Failure Trial: Rationale and design. <i>American Heart Journal</i> , 2014, 168, 645-651.e1.	1.2	45
331	Clinical Profile and Prognostic Value of Anemia at the Time of Admission and Discharge Among Patients Hospitalized for Heart Failure With Reduced Ejection Fraction. <i>Circulation: Heart Failure</i> , 2014, 7, 401-408.	1.6	34
332	Torsemide vs. Furosemide in Heart Failure Patients: Insights from Duke University Hospital. <i>Journal of Cardiac Failure</i> , 2014, 20, S95.	0.7	0
333	Mineralocorticoid Receptor Antagonist Use in Hospitalized Patients With Heart Failure, Reduced Ejection Fraction, and Diabetes Mellitus (from the EVEREST Trial). <i>American Journal of Cardiology</i> , 2014, 114, 743-750.	0.7	8
334	Sleep-Disordered Breathing in Patients with Heart Failure. <i>Heart Failure Clinics</i> , 2014, 10, 243-250.	1.0	13
335	International differences in clinical characteristics, management, and outcomes in acute heart failure patients: better short-term outcomes in patients enrolled in Eastern Europe and Russia in the PROTECT trial. <i>European Journal of Heart Failure</i> , 2014, 16, 614-624.	2.9	71
336	Charting a Roadmap for Heart Failure Biomarker Studies. <i>JACC: Heart Failure</i> , 2014, 2, 477-488.	1.9	81
337	Designing effective drug and device development programs for hospitalized heart failure: A proposal for pretrial registries. <i>American Heart Journal</i> , 2014, 168, 142-149.	1.2	34
338	Site selection in global clinical trials in patients hospitalized for heart failure: perceived problems and potential solutions. <i>Heart Failure Reviews</i> , 2014, 19, 135-152.	1.7	48
339	Funding opportunities for clinical investigators in the early stages of career development in cardiovascular research. <i>Journal of Thrombosis and Thrombolysis</i> , 2013, 36, 527-532.	1.0	4
340	Association of Beta-Blocker Use and Selectivity With Outcomes in Patients With Heart Failure and Chronic Obstructive Pulmonary Disease (from OPTIMIZE-HF). <i>American Journal of Cardiology</i> , 2013, 111, 582-587.	0.7	71
341	Comparable Clinical Benefits with Beta-Blockers in Heart Failure Patients from North America and Europe: Evidence from a Meta-Analysis of Randomized Clinical Trials. <i>Journal of Cardiac Failure</i> , 2013, 19, S28.	0.7	0
342	Learning from recent trials and shaping the future of acute heart failure trials. <i>American Heart Journal</i> , 2013, 166, 629-635.	1.2	30

#	ARTICLE	IF	CITATIONS
343	Noncardiac Comorbidities and Acute Heart Failure Patients. <i>Heart Failure Clinics</i> , 2013, 9, 359-367.	1.0	52
344	Clinical characteristics, response to exercise training, and outcomes in patients with heart failure and chronic obstructive pulmonary disease: Findings from Heart Failure and A Controlled Trial Investigating Outcomes of Exercise TraiNing (HF-ACTION). <i>American Heart Journal</i> , 2013, 165, 193-199.	1.2	77
345	Predictors of early dyspnoea relief in acute heart failure and the association with 30-day outcomes: findings from ASCEND-HF. <i>European Journal of Heart Failure</i> , 2013, 15, 456-464.	2.9	39
346	Influence of documented history of coronary artery disease on outcomes in patients admitted for worsening heart failure with reduced ejection fraction in the EVEREST trial. <i>European Journal of Heart Failure</i> , 2013, 15, 61-68.	2.9	21
347	The past, present and future of renin-angiotensin aldosterone system inhibition. <i>International Journal of Cardiology</i> , 2013, 167, 1677-1687.	0.8	97
348	Race, exercise training, and outcomes in chronic heart failure: Findings from Heart Failure - A Controlled Trial Investigating Outcomes in Exercise TraiNing (HF-ACTION). <i>American Heart Journal</i> , 2013, 166, 488-495.e1.	1.2	29
349	Response to Global cardiovascular clinical trials and geographic altitude. <i>American Heart Journal</i> , 2013, 165, e15.	1.2	0
350	SERUM MAGNESIUM LEVELS AND POSTDISCHARGE OUTCOMES IN PATIENTS HOSPITALIZED FOR HEART FAILURE: INSIGHTS FROM THE EVEREST TRIAL. <i>Journal of the American College of Cardiology</i> , 2013, 61, E631.	1.2	0
351	Relationship Between Clinical Trial Site Enrollment With Participant Characteristics, Protocol Completion, and Outcomes. <i>Journal of the American College of Cardiology</i> , 2013, 61, 571-579.	1.2	58
352	Â-blockers for heart failure: which works best?. <i>BMJ</i> , The, 2013, 346, f480-f480.	3.0	1
353	Dysphagia in the Setting of Left Ventricular Assist Device Hemolysis. <i>ASAIO Journal</i> , 2013, 59, 322-323.	0.9	5
354	Is There a Rationale for Antiplatelet Therapy in Acute Heart Failure?. <i>Circulation: Heart Failure</i> , 2013, 6, 869-876.	1.6	5
355	Haemoconcentration, renal function, and postdischarge outcomes among patients hospitalized for heart failure with reduced ejection fraction: insights from the EVEREST trial. <i>European Journal of Heart Failure</i> , 2013, 15, 1401-1411.	2.9	119
356	Association between diabetes mellitus and postdischarge outcomes in patients hospitalized with heart failure: findings from the EVEREST trial. <i>European Journal of Heart Failure</i> , 2013, 15, 194-202.	2.9	155
357	The PROTECT in-hospital risk model: 7-day outcome in patients hospitalized with acute heart failure and renal dysfunction. <i>European Journal of Heart Failure</i> , 2012, 14, 605-612.	2.9	115
358	Clinical characteristics and outcomes of hospitalized heart failure patients with systolic dysfunction and chronic obstructive pulmonary disease: findings from OPTIMIZE-HF. <i>European Journal of Heart Failure</i> , 2012, 14, 395-403.	2.9	85
359	Bronchodilators in Heart Failure Patients With COPD: Is It Time for a Clinical Trial?. <i>Journal of Cardiac Failure</i> , 2012, 18, 413-422.	0.7	33
360	The Impact of Chronic Obstructive Pulmonary Disease in Patients Hospitalized for Worsening Heart Failure With Reduced Ejection Fraction: An Analysis of the EVEREST Trial. <i>Journal of Cardiac Failure</i> , 2012, 18, 515-523.	0.7	62

#	ARTICLE	IF	CITATIONS
361	Implications of geographical variation on clinical outcomes of cardiovascular trials. American Heart Journal, 2012, 164, 303-312.	1.2	44
362	Atrial fibrillation or flutter on initial electrocardiogram is associated with worse outcomes in patients admitted for worsening heart failure with reduced ejection fraction: Findings from the EVEREST Trial. American Heart Journal, 2012, 164, 884-892.e2.	1.2	24
363	Diuretics and Ultrafiltration in Acute Decompensated Heart Failure. Journal of the American College of Cardiology, 2012, 59, 2145-2153.	1.2	142
364	Gender Does Not Affect Postdischarge Outcomes in Patients Hospitalized for Worsening Heart Failure With Reduced Ejection Fraction (from the Efficacy of Vasopressin Antagonism in Heart Failure) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 61.	1.0	10
365	Comparison of Clinical Characteristics and Long-Term Outcomes of Patients With Ischemic Cardiomyopathy With Versus Without Angina Pectoris (from the Duke Databank for Cardiovascular) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50 61.	1.0	10
366	Cardiorenal Syndrome Clinical Trial End Points. Heart Failure Clinics, 2011, 7, 519-528.	1.0	5
367	Epidemiology of Cardiorenal Syndrome. Cardiology Clinics, 2011, 29, 301-314.	0.9	9
368	Association between VE-VCO2 Slope and Resting Hemodynamic Measurements in Ambulatory Heart Failure (HF) Patients: An Analysis from the Duke Advanced HF Database. Journal of Cardiac Failure, 2011, 17, S8-S9.	0.7	0
369	Clinical Characteristics and Outcomes of Patients with Ischemic Cardiomyopathy (ICM) and Angina: Findings from the Duke Cardiovascular Database. Journal of Cardiac Failure, 2011, 17, S81-S82.	0.7	0
370	Clinical Characteristics and Outcomes for Hospitalized Heart Failure (HF) Patients with Chronic Obstructive Pulmonary Disease (COPD): Findings from OPTIMIZE-HF. Journal of Cardiac Failure, 2011, 17, S86-S87.	0.7	0
371	International Differences in Acute Heart Failure (AHF) Patients: Insight from the PROTECT Trial. Journal of Cardiac Failure, 2011, 17, S59-S60.	0.7	0
372	Natriuretic Peptide-Guided Therapy for Heart Failure. Circulation Journal, 2011, 75, 2031-2037.	0.7	13
373	Epidemiology of Cardiorenal Syndrome. Heart Failure Clinics, 2010, 6, 333-346.	1.0	14